Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors
Open Access
- 17 November 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 8 (1), 1-8
- https://doi.org/10.1186/1476-4598-8-105
Abstract
With the aim to simplify cancer management, cancer research lately dedicated itself more and more to discover and develop non-invasive biomarkers. In this connection, circulating cell-free DNA (ccf DNA) seems to be a promising candidate. Altered levels of ccf nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) have been found in several cancer types and might have a diagnostic value. Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls. To evaluate the applicability of plasma ccf nDNA and mtDNA as a biomarker for distinguishing between the three study-groups we performed ROC (Receiver Operating Characteristic) curve analysis. We also compared the levels of both species in the cancer group with clinicopathological parameters. While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022). The level of ccf nDNA was also associated with tumor-size (2 cm<5 cm; 2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034). Using ROC curve analysis, we were able to distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker (cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%; specificity: 87%; P < 0.001). Our data suggests that nuclear and mitochondrial ccf DNA have potential as biomarkers in breast tumor management. However, ccf nDNA shows greater promise regarding sensitivity and specificity.Keywords
This publication has 38 references indexed in Scilit:
- Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controlsNeuroImage, 2009
- Simultaneous quantitative assessment of circulating cell-free mitochondrial and nuclear DNA by multiplex real-time PCRGenetics and Molecular Biology, 2009
- Quantification of Free Circulating Tumor DNA as a Diagnostic Marker for Breast CancerDNA and Cell Biology, 2008
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast CancerJAMA, 2008
- Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cellsThe Prostate, 2008
- Regulation of mitochondrial DNA content and cancerMitochondrion, 2006
- Association of decreased mitochondrial DNA content with ovarian cancer progressionBritish Journal of Cancer, 2006
- Cancer biomarkers: a systems approachNature Biotechnology, 2006
- CA 125, CA 15.3, CA 27.29, CEA, β-hCG and α-fetoprotein levels in cyst fluid of breast macrocystsInternational Journal of Gynecology & Obstetrics, 1995